Elena Ratner MD

Assistant Professor of Obstetrics, Gynecology, and Reproductive Sciences

Specialties & Subspecialties

Cancer Center, Yale: Gynecologic Oncology Program

Obstetrics, Gynecology & Reproductive Sciences: Gynecologic Oncology: Sexuality, Intimacy and Menopause Program | Ovarian Cancer Program, Early Detection

Education & Training

  • B.S., Barnard College, Columbia University (1998)
  • M.D., State University of NY Medical College (2003)
  • Fellowship, Yale University School of Medicine , Gynecologic Oncology (2007 - 2010)
  • Residency, Yale-New Haven Hospital , Obstetrics & Gynecology (2004 - 2007)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult, Adolescent | Accepts referrals from patients


Clinical Interests

ovarian cancer; uterine cancer; cervical cancer; cancer prevention; cancer prophylaxis; genetic risk factors; sexuality; menopause; early cancer detection


Cancers Treated

Cervix, Ovary, Uterus


Board Certifications

  • Obstetrics & Gynecology, Board Certified (2012)

Clinical Trials

ConditionsStudy Title
Chordoma, Desmoid Tumor, Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, and Soft TissueA COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol (COG 9902)
Endometrial Cancer and Corpus UteriA Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma (GOG 0258) (CIRB)
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

More Clinical Trials...

Edit Profile